| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/22/2005 | EP1007533B1 Bioconjugates and delivery of bioactive agents |
| 06/22/2005 | EP0892644B1 In vivo gene transfer methods for wound healing |
| 06/22/2005 | CN1630730A Methods for detecting and treating the early onset of aging-related conditions |
| 06/22/2005 | CN1630728A Buffer solution for electroporation and a method comprising the use of the same |
| 06/22/2005 | CN1630724A Compositions and methods for inhibiting expression of a target gene |
| 06/22/2005 | CN1630716A Hematopoietic cells from human embryonic stem cells |
| 06/22/2005 | CN1630664A Caspase-8 binding protein, its preparation and use |
| 06/22/2005 | CN1630663A Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 06/22/2005 | CN1630538A Stimulation of vascularization with VEGF-B |
| 06/22/2005 | CN1630535A Inhibition of STAT-1 |
| 06/22/2005 | CN1630529A B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies |
| 06/22/2005 | CN1630494A Ophthalmic drug delivery device |
| 06/22/2005 | CN1629296A Recombinant vaccine using flavivirus as vector |
| 06/22/2005 | CN1629285A Natural killer cell for transgenic expression cell chemotactic factors |
| 06/22/2005 | CN1629185A Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 06/22/2005 | CN1628859A 杂交酵母癌症疫苗 Hybrid yeast cancer vaccine |
| 06/22/2005 | CN1628858A Method for inducing immune response using HBs DNA vaccine inoculated by HBV core protein reinforcing gene gun |
| 06/22/2005 | CN1628857A Follicular granulosa cell anti-senescence technology |
| 06/22/2005 | CN1207302C Method and compounds for curing diseases caused by mutations |
| 06/21/2005 | US6908987 Comprises nucleotide sequences coding peroxisome proliferator activator receptor protein (PCG) for modulating thermogenesis in adipocytes and treating obesity |
| 06/21/2005 | US6908765 Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same |
| 06/21/2005 | US6908741 Receptor for advanced glycated endproducts (RAGE); solid phase synthesis; immunoassay |
| 06/21/2005 | US6908623 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/21/2005 | US6908616 Composition suitable for immunizing crustaceans by injection against White Spot Syndrome Virus, WSSV, comprising isolated protein consisting of specified amino acid sequence, which delays mortality against WSSV infectivity in crustaceans |
| 06/21/2005 | US6908612 Virus coat protein/receptor chimeras and methods of use |
| 06/21/2005 | CA2182303C Method of preparing a viral vector by homologous intermolecular recombination |
| 06/16/2005 | WO2005054486A1 Method of preparing gene transfer reagent |
| 06/16/2005 | WO2005054485A2 Adenovirus-transfected primary cells and methods of pathway mapping |
| 06/16/2005 | WO2005054484A1 Promoters for expression in modified vaccinia virus ankara |
| 06/16/2005 | WO2005054432A2 Gene transfer for regulating smooth muscle tone |
| 06/16/2005 | WO2005053744A1 TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR 1α ANTAGONISTS |
| 06/16/2005 | WO2005053662A1 Dna damage repair inhibitors for treatment of cancer |
| 06/16/2005 | WO2005040333A3 Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism |
| 06/16/2005 | WO2005039642B1 Dna delivery with gemini cationic surfactants |
| 06/16/2005 | WO2005024032A3 Targeting adenoviral vectors to dendritic cells |
| 06/16/2005 | WO2005023180A3 Method for detecting cancer cells and monitoring cancer therapy |
| 06/16/2005 | WO2005018650A3 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 06/16/2005 | WO2005018571A3 Compositions and methods for treating inflammatory lung disease |
| 06/16/2005 | WO2005014645A3 Pedf-r receptor and uses |
| 06/16/2005 | WO2005007098A3 Nucleic acid therapy to enhance cartilage repair |
| 06/16/2005 | WO2005000235A3 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME |
| 06/16/2005 | WO2004108840A8 Nucleotides for prevention and treatment of bacterial and fungal pathologies |
| 06/16/2005 | WO2004081199A3 Novel compositions and methods for the treatment of immune related disease |
| 06/16/2005 | WO2004064501A3 Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins |
| 06/16/2005 | WO2004060280A3 Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
| 06/16/2005 | WO2004047855A3 Proteins involved in the regulation of energy homeostasis |
| 06/16/2005 | WO2004035006A3 Methods and compositions for immunization against hiv |
| 06/16/2005 | US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/16/2005 | US20050131212 Neurogenic peptide for use in enhancement of neuronal migration, proliferation, survival, differentiation, and/or neurite outgrowth |
| 06/16/2005 | US20050131200 Biocompatability; polyphosphoester/polyphosphoramidate linkages; improved gene delivery into muscles; DNA vaccines |
| 06/16/2005 | US20050130972 Derivatives have a positive charge at the position corresponding to the anomeric position of a pyranose ring; active-site specific chaperones for mutant glucocerebrosidase |
| 06/16/2005 | US20050130929 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 06/16/2005 | US20050130928 Modulating mammalian midkine activity; alters pulmonary vasculature development and smooth muscle cell development |
| 06/16/2005 | US20050130927 For treating neoplasm, hypoproliferation, hyperproliferation, degenerative and neurodegenerative diseases, ischaemia, immune system disorder, infectious disease, or metabolic dysfunction |
| 06/16/2005 | US20050130925 Transduction; prostaglandins E1 (PGE1); introducing a recombinant cDNA encoding at least one cyclooxygenase isoform into the cells such that cells overexpress cyclooxygenase isoform then treating cells with fatty acid substrate |
| 06/16/2005 | US20050130923 4'-thionucleosides and oligomeric compounds |
| 06/16/2005 | US20050130919 Allow for inhibition of the expression of target alleles in a spatially and temporally regulatable manner; useful for investigating gene functions; genetic engineering |
| 06/16/2005 | US20050130916 Nucleic acid coding for the cgl1 polypeptide and diagnostic and therapeutic application of said nucleic acid and of the cgl1 polypeptide |
| 06/16/2005 | US20050130911 Nucleic acid-lipophilic conjugates |
| 06/16/2005 | US20050130306 Conditionally replication-competent viral vector for use as gene transfer tool in genetic engineering |
| 06/16/2005 | US20050130304 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 06/16/2005 | US20050130302 Method and composition for regulating expansion of stem cells |
| 06/16/2005 | US20050130286 For diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders |
| 06/16/2005 | US20050130265 Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| 06/16/2005 | US20050130195 Functional molecule and process for producing the same |
| 06/16/2005 | US20050130189 Using chromic visceral hypersensitivity (CVH) polypeptide concentration as diagnostic tool in detection of inflammatory disorders |
| 06/16/2005 | US20050130130 Killer cell activatory receptor ligand for use in diagnosis, prevention and treatment of infection, cell proliferative, autoimmune and arthritic disorders |
| 06/16/2005 | US20050130129 Targeting gene transfer vectors to certain cell types by pseudotyping with viral glycoprotein |
| 06/16/2005 | US20050130128 Methods for detecting NEBR1 expression in a biological sample by contacting a sample with the labeled antibody; inhibits HIV replication in host cells |
| 06/16/2005 | US20050130127 Coronavirus-like particles comprising functionally deleted genomes |
| 06/16/2005 | US20050130123 Methods of examining (-) strand rna virus vectors having lowered ability to form grains and method of constructing the same |
| 06/16/2005 | US20050129717 Novel uses |
| 06/16/2005 | US20050129713 For use in vaccine |
| 06/16/2005 | US20050129694 At least one (SEK) kinase inhibitor that acts in an synergistic manner to those inhibiting the virus multiplication for the Raf/MEK/ERK signal transmission path; influenza viricides |
| 06/16/2005 | US20050129681 Inhibiting endothelial cell adhesion and migration; limit specific binding of integrin alpha 4 beta 1; antitumor |
| 06/16/2005 | US20050129673 Chondrocyte cell-lines |
| 06/16/2005 | US20050129672 For isolating an enriched or purified population of motor neurons from a mixed population of human brain and/or spinal cells; for therapeutically targeting motor neurons eg myeloradiculopathy |
| 06/16/2005 | US20050129671 Mammalian antigen-presenting T cells and bi-specific T cells |
| 06/16/2005 | US20050129669 Gene therapy; comprising a targeting sequence, a regulatory sequence, an exon and an unpaired splice-donor site |
| 06/16/2005 | US20050129667 treating leukemia or bone cancer by injecting a samarium comples of ethylenediaminetetramethanephosphonic acid and another chemotherapeutic agent; stem cell/bone marrow transplantation and/or restoration; patient is not subjected to total body irradiation |
| 06/16/2005 | US20050129666 Compositions comprising preconditioned myoblasts having enhanced fusion properties |
| 06/16/2005 | US20050129665 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| 06/16/2005 | US20050129661 For gene therapy; cochleates containing rep proteins and DNA with inverted terminal repeats (ITRs) for use as a vector for efficient delivery of genes |
| 06/16/2005 | US20050129660 For gene therapy by transfection; forming an occlusion of fluid flow in a limb; inserting a viral vector into the lumen of a vein or artery in said limb, thereby forcing fluid into the extravascular space, releasing the occlusion |
| 06/16/2005 | DE10353887A1 Hochparalleler DNA-Synthesizer auf Matrizenbasis Highly parallel DNA synthesizer to die base |
| 06/16/2005 | CA2548135A1 Synthetic hla binding peptide analogues and uses thereof |
| 06/16/2005 | CA2547537A1 Protein nmb0928 and use thereof in pharmaceutical formulations |
| 06/16/2005 | CA2547355A1 Animal models of pancreatic adenocarcinoma and uses therefor |
| 06/16/2005 | CA2547317A1 Protein nmb1125 and use thereof in pharmaceutical formulations |
| 06/16/2005 | CA2547077A1 Dna damage repair inhibitors for treatment of cancer |
| 06/16/2005 | CA2546680A1 Promoters for expression in modified vaccinia virus ankara |
| 06/16/2005 | CA2546649A1 Treatment of rheumatoid arthritis with hypoxia-inducible factor 1.alpha. antagonists |
| 06/16/2005 | CA2546452A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 06/15/2005 | EP1541690A2 Transfer of mRNA using polycationic compounds |
| 06/15/2005 | EP1541135A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 06/15/2005 | EP1540333A2 Maxs as modifiers of the axin pathway and methods of use |
| 06/15/2005 | EP1540332A1 Methods of screening compounds for grk6 modulating activity |
| 06/15/2005 | EP1540008A2 Fluorescent proteins, nucleic acids encoding them and methods for making and using them |
| 06/15/2005 | EP1540004A2 Double stranded rna structures and constructs, and methods for generating and using the same |
| 06/15/2005 | EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |